Thomas Schinecker, CEO of Swiss pharmaceutical company Roche, has confirmed that the company has no plans for layoffs and maintains a healthy business status. Despite a significant drop in Roche's stock price from its peak in April 2022, Schinecker assured that the workforce remains stable, with a slight increase in numbers.
Addressing concerns about Roche's drug development setbacks, particularly in cancer treatment, Schinecker emphasized that the company's research and development budget remains stable, with no growth issues. The anticipated launch of Roche's weight-loss drug is projected around 2029 or earlier.
Looking at the broader economic outlook, Schinecker noted challenges in Europe, especially given Germany's recent economic difficulties. He acknowledged growth in the U.S. economy, but emphasized that Europe requires more time to recover.
